Takeda Head Blames Own Structural Problems For Foreign Drug Delays
This article was originally published in PharmAsia News
Executive Summary
Takeda's president says structural differences among pharmaceutical companies from different countries, including Japan, are responsible for approval delays faced by many drug makers in the United States. Yasuchika Hasegawa said his own company is analyzing its responsibility in the delays, and plans discussions with U.S. FDA about approval timelines and details of clinical trials as part of an effort to correct Takeda's structural deficiencies. Astellas Pharma and Daiichi Sankyo are other major Japanese drug makers that have complained about delays hampering their plans for expansion abroad. (Click here for more - a subscription may be required